Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency

Novo Nordisk

Status: Completed

Conditions: Menopause; Postmenopausal Vaginal Atrophy

Treatments: Drug: estradiol, 25 mcg

Study type: Observational

Funder types: Industry

Identifiers

NCT01507454

VAG-1935

Details and patient eligibility

About

This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.

Enrollment: 1,613 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Atrophic vaginitis due to estrogen deficiency
• Post-menopausal

Trial design

1,613 participants in 1 patient group

Local treatment

Treatment:

Drug: estradiol, 25 mcg